Last reviewed · How we verify
NCT02431715
18F-FDOPA PET in Neuroendocrine Tumours
trial testing [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) in Thyroid Cancer, Medullary. No longer available.
Quick facts
| Lead sponsor | British Columbia Cancer Agency |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across Canada |
Drugs / interventions tested
- [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) — full drug profile →
Conditions studied
- Thyroid Cancer, Medullary — all drugs for Thyroid Cancer, Medullary →
- Carcinoid Tumor — all drugs for Carcinoid Tumor →
- Pheochromocytoma — all drugs for Pheochromocytoma →
- Paraganglioma — all drugs for Paraganglioma →
Sponsor
British Columbia Cancer Agency
Who can join
1 Month and older, any sex, with Thyroid Cancer, Medullary or Carcinoid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic. The correct treatment approach is dependent on the extent of the disease, however surgical approaches and systemic therapy can be curative. Combined positron emission tomography/computed tomography (PET/CT) using the radiotracer 18F-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) has been shown to be a promising non-invasive technique to help localizing NETs and guide their treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A side-by-side evaluation of [<sup>18</sup>F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography.
Narayan A, Yan Y, Lisok A, Brummet M, et al · · 2019 · cited 3× · PMID 31645896 · DOI 10.18632/oncotarget.27184
Verify or expand the search:
- PubMed search for NCT02431715
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other British Columbia Cancer Agency trials
Trials by the same sponsor.
- NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
- NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
- NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
- NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
- NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02431715 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
- Last refreshed: 21 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02431715.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing